View Filing Data

Document And Entity Information - shares	9 Months Ended
Document And Entity Information - shares	Sep. 30, 2018	Nov. 08, 2018
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2018
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	Q3
Entity Registrant Name	EYENOVIA, INC.
Entity Central Index Key	0001682639
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Trading Symbol	EYEN
Entity Common Stock, Shares Outstanding		10,088,996
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Small Business	true

Condensed Balance Sheets - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Current Assets:
Cash	$ 21,044,135	$ 5,249,511
Prepaid expenses and other current assets	298,450	37,149
Total Current Assets	21,342,585	5,286,660
Property and equipment, net	11,152	27,960
Deferred offering costs	0	328,700
Security deposit	117,800	0
Total Assets	21,471,537	5,643,320
Current Liabilities:
Accounts payable	840,230	246,384
Accrued expenses and other current liabilities	888,984	306,263
Total Current Liabilities	1,729,214	552,647
Deferred rent	2,332	0
Total Liabilities	1,731,546	552,647
Commitments and contingencies (Note 5)
Stockholders' Equity:
Common stock, $0.0001 par value, 90,000,000 shares authorized; 10,088,996 and 2,566,530 shares issued and outstanding as of September 30, 2018 and December 31, 2017, respectively	1,009	257
Additional paid-in capital	50,070,169	24,351,138
Accumulated deficit	(30,331,187)	(19,261,186)
Total Stockholders' Equity	19,739,991	5,090,673
Total Liabilities and Stockholders' Equity	21,471,537	5,643,320
Series A Convertible Preferred Stock [Member]
Stockholders' Equity:
Preferred Stock Value	0	293
Series A-2 Convertible Preferred Stock [Member]
Stockholders' Equity:
Preferred Stock Value	0	79
Series B Convertible Preferred Stock [Member]
Stockholders' Equity:
Preferred Stock Value	$ 0	$ 92

Condensed Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2018	Dec. 31, 2017
Preferred Stock, Par or Stated Value Per Share	$ 0.0001	$ 0.0001
Preferred Stock, Shares Authorized	6,000,000	6,000,000
Common Stock, Par or Stated Value Per Share	$ 0.0001	$ 0.0001
Common Stock, Shares Authorized	90,000,000	90,000,000
Common Stock, Shares, Issued	10,088,996	2,566,530
Common Stock, Shares, Outstanding	10,088,996	2,566,530
Series A Convertible Preferred Stock [Member]
Preferred Stock Designated Shares	0	20,000,000
Preferred Stock, Shares Issued	0	2,932,431
Preferred Stock, Shares Outstanding	0	2,932,431
Series A-2 Convertible Preferred Stock [Member]
Preferred Stock Designated Shares	0	5,714,286
Preferred Stock, Shares Issued	0	788,827
Preferred Stock, Shares Outstanding	0	788,827
Series B Convertible Preferred Stock [Member]
Preferred Stock Designated Shares	0	10,000,000
Preferred Stock, Shares Issued	0	918,983
Preferred Stock, Shares Outstanding	0	918,983

Condensed Statements of Operations - USD ($)	3 Months Ended		9 Months Ended
Condensed Statements of Operations - USD ($)	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Operating Expenses:
Research and development	$ 2,487,573	$ 570,422	$ 6,993,832	$ 2,233,193
General and administrative	1,832,794	314,859	4,079,249	735,759
Total Operating Expenses	4,320,367	885,281	11,073,081	2,968,952
Loss From Operations	(4,320,367)	(885,281)	(11,073,081)	(2,968,952)
Other Income (Expense):
Interest income (expense)	(964)	665	3,080	1,396
Net Loss	$ (4,321,331)	$ (884,616)	$ (11,070,001)	$ (2,967,556)
Net Loss Per Share
- Basic and Diluted	$ (0.43)	$ (0.10)	$ (1.20)	$ (0.35)
Weighted Average Number of Common Shares Outstanding
- Basic and Diluted	10,030,296	8,514,906	9,219,818	8,514,906

Condensed Statements of Cash Flows - USD ($)

9 Months Ended

Sep. 30, 2018

Sep. 30, 2017

Cash Flows From Operating Activities

Net loss

$ (11,070,001)

$ (2,967,556)

Adjustments to reconcile net loss to net cash used in operating activities:

Depreciation and amortization

16,808

12,336

Stock-based compensation

1,115,034

212,411

Changes in operating assets and liabilities:

Prepaid expenses and other current assets

(261,301)

(132,506)

Accounts payable

593,846

19,601

Accrued expenses and other current liabilities

715,721

117,734

Security deposits

(117,800)

Deferred rent

2,332

Net Cash Used In Operating Activities

(9,005,361)

(2,737,980)

Cash Flows From Investing Activities

Purchases of property and equipment

(3,262)

Net Cash Used In Investing Activities

(3,262)

Cash Flows From Financing Activities

Proceeds from sale of common stock in initial public offering

^[1]

25,089,000

Proceeds from exercise of stock options

56,482

Proceeds from sale of warrant

431,574

Proceeds from advances

6,409,651

Payment of initial public offering issuance costs

(345,497)

(81,237)

Net Cash Provided By Financing Activities

24,799,985

6,759,988

Net Increase in Cash

15,794,624

4,018,746

Cash - Beginning of Period

5,249,511

3,387,288

Cash - End of Period

21,044,135

7,406,034

Supplemental Disclosure of Non-Cash Financing Activities

Conversion of convertible preferred stock into common stock

470

Exercise of warrants on a cashless basis

Accrual of deferred offering costs

33,000

Reversal of previously accrued initial public offering issuance costs

(133,000)

Reduction of additional paid-in capital for initial public offering issuance costs that were previously paid

$ (195,700)

$ 0

[1]	Includes gross proceeds of $27,300,000, less issuance costs of $2,211,000 deducted directly from the offering proceeds.

Summary of Significant Accounting Policies

9 Months Ended

Sep. 30, 2018

Accounting Policies [Abstract]

Significant Accounting Policies [Text Block]

Note 2 – Summary of Significant Accounting Policies

The Company’s significant accounting policies are disclosed in Note 2 – Summary of Significant Accounting Policies in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017. Since the date of the Annual Report, there have been no material changes to the Company’s significant accounting policies, except as disclosed below.

Liquidity and Financial Condition

The Company has not yet generated revenues or achieved profitability and expects to continue to incur cash outflows from operations. It is expected that its research and development and general and administrative expenses will continue to increase and, as a result, the Company will eventually need to generate significant product revenues to achieve profitability. On January 29, 2018, the Company raised aggregate net proceeds of approximately $24.5 million in its initial public offering (“IPO”). See Note 7 – Stockholders’ Equity – Initial Public Offering for additional details.

The Company believes its current cash on hand is sufficient to meet its operating and capital requirements for at least the next twelve months from the date these financial statements are issued. Thereafter, the Company may need to raise further capital, through the sale of additional equity or debt securities or otherwise, to support its future operations. The Company’s operating needs include the planned costs to operate its business, including amounts required to fund working capital and capital expenditures. The Company’s future capital requirements and the adequacy of its available funds will depend on many factors, including the Company’s ability to successfully commercialize its products and services, competing technological and market developments, and the need to enter into collaborations with other companies or acquire other companies or technologies to enhance or complement our product and service offerings. If the Company is unable to secure additional capital, it may be required to curtail its research and development initiatives and take additional measures to reduce costs in order to conserve its cash.

Cash

The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents in the financial statements. As of September 30, 2018 and December 31, 2017, the Company had no cash equivalents.

The Company has cash deposits in several financial institutions which, at times, may be in excess of Federal Deposit Insurance Corporation (“FDIC”) insurance limits. The Company has not experienced losses in such accounts and periodically evaluates the creditworthiness of its financial institutions. As of September 30, 2018 and December 31, 2017, the Company had cash balances in excess of FDIC insurance limits of $20,794,135 and $4,999,511, respectively.

Reclassifications

Certain prior period balances have been reclassified in order to conform to current period presentation. These reclassifications have no effect on previously reported results of operations or loss per share.

Net Loss Per Common Share

Basic net loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the period. Diluted earnings per share reflects the potential dilution that could occur if securities or other instruments to issue common stock were exercised or converted into common stock.

The following securities are excluded from the calculation of weighted average diluted common shares because their inclusion would have been anti-dilutive:

	September 30,
	2018		2017
Options		2,225,118		1,684,409
Series A Convertible Preferred Stock		-		2,932,431
Series A-2 Convertible Preferred Stock		-		788,827
Series B Convertible Preferred Stock		-		918,949
Total potentially dilutive shares		2,225,118		6,324,616

Recent Accounting Pronouncements

In May 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2017-09, “Compensation—Stock Compensation (Topic 718): Scope of Modification Accounting” (“ASU 2017-09”). ASU 2017-09 provides clarity on the accounting for modifications of stock-based awards. ASU 2017-09 requires adoption on a prospective basis in the annual and interim periods for our fiscal year ending after December 15, 2017 for share-based payment awards modified on or after the adoption date. The Company adopted this standard on January 1, 2018 and its adoption did not have a material impact on the Company’s financial position, results of operations or cash flows.

In June 2018, the FASB issued ASU No. 2018-07, “Compensation — Stock Compensation (Topic 718),” (“ASU 2018-07”). ASU 2018-07 is intended to reduce cost and complexity of financial reporting for non-employee share-based payments. Currently, the accounting requirements for non-employee and employee share-based payments are significantly different. ASU 2018-07 expands the scope of Topic 718, which currently only includes share-based payments to employees, to include share-based payments to non-employees for goods or services. Consequently, the accounting for share-based payments to non-employees and employees will be substantially aligned. This ASU supersedes Subtopic 505-50, “Equity — Equity-Based Payments to Nonemployees”. The amendments to ASU 2018 - 07 are effective for fiscal years beginning after December 15, 2019, and interim periods within fiscal years beginning after December 15, 2020. Early adoption is permitted, but no earlier than a company’s adoption date of ASU No. 2014-09, (Topic 606), “Revenue from Contracts with Customers”. The Company is currently evaluating ASU 2018-07 and its impact on its financial position, results of operations and cash flows.

In July 2018, the FASB issued ASU No. 2018-10, “Codification Improvements to Topic 842, Leases,” (“ASU 2018-10”). The amendments in ASU 2018-10 are to address stakeholders’ questions about how to apply certain aspects of the new guidance in ASC 842. The clarifications address the rate implicit in the lease, impairment of the net investment in the lease, lessee reassessment of lease classification, lessor reassessment of lease term and purchase options, variable payments that depend on an index or rate and certain transition adjustments. The amendments in ASC Topic 842

are effective for emerging growth companies for fiscal years beginning

after December 15, 2019. The Company is currently evaluating ASU 2018-10 and its impact on its financial position, results of operations and cash flows.

In July 2018, the FASB issued ASU No. 2018-11, “Leases (Topic 842): Targeted Improvements,” (“ASU 2018-11”). The amendments in ASU 2018-11 related to transition relief on comparative reporting at adoption affect all entities with lease contracts that choose the additional transition method and separating components of a contract affect only lessors whose lease contracts qualify for the practical expedient. The amendments in ASC Topic 842

are effective for emerging growth companies for fiscal years beginning

after December 15, 2019. The Company is currently evaluating ASU 2018-11 and its impact on its financial position, results of operations and cash flows.

In August 2018, the FASB issued ASU No. 2018-13, “Fair Value Measurement (Topic 820): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement (“ASU 2018-13”). The amendments in ASU 2018-13 modify the disclosure requirements on fair value measurements based on the concepts in the Concepts Statement, including the consideration of costs and benefits. The amendments on changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments should be applied retrospectively to all periods presented upon their effective date. The amendments are effective for fiscal years beginning after December 15, 2020. Early adoption is permitted, including adoption in an interim period. The Company is currently evaluating ASU 2018-13 and its impact on its financial position, results of operations and cash flows.

Related Party Transactions

9 Months Ended

Sep. 30, 2018

Note 6 – Related Party Transactions

Consulting Agreements

The Company’s Chief Executive Officer and a member of its Board of Directors are partners in Private Medical Equity, Inc. (“PME”). The Company and PME were parties to a consulting agreement dated November 4, 2014 that provided for the payment of $33,200 per month to PME in consulting fees for general management and strategy services. Any time spent by PME in excess of the specified amount is billed separately. During the three and nine months ended September 30, 2017, the Company incurred approximately $47,000 and $329,000, respectively, related to the agreement, of which, $25,192 and $176,344, respectively, was included within research and development expenses and $21,808 and $152,656, respectively, was included within general and administrative expenses on the condensed statements of operations. On August 1, 2017, the agreement was terminated and the Company’s Chief Executive Officer became employed full time by the Company. The Board member now bills the Company through a separate consulting agreement dated July 6, 2017 that is discussed below.

A company in which a member of the Company’s Board of Directors is part owner is a party to a consulting agreement with the Company dated July 6, 2017 that provides for the payment of $9,567 per month, and $250 per hour for any additional work, for advisory services performed by such director. The Company incurred expenses of $35,018 and $25,509 for the three months ended September 30, 2018 and 2017, respectively, and $127,478 and $25,509 for the nine months ended September 30, 2018 and 2017, respectively, related to the agreement which was included within general and administrative expenses on the condensed statement of operations.

Lease Agreements

The Company paid $3,000 and $4,000 per month as of July 2016 and January 2018, respectively, to a company controlled by a member of its Board of Directors for office space in New York, New York for its Chief Executive Officer. The Company left the space on August 31, 2018. The Company’s rent expense for this space amounted to $8,000 and $9,000 for the three months ended September 30, 2018 and 2017, respectively, and $32,000 and $27,000 for the nine months ended September 30, 2018 and 2017, respectively, related to the office space, which was included within general and administrative expenses on the condensed statement of operations.

The Company’s Vice President of Research and Development (“VP of R&D”) owns a company that entered into a lease agreement with the Company on September 15, 2016 to lease 953 square feet of space located in Reno, NV with respect to its research and development activities. The initial monthly base rent was $3,895 per month over the term of the lease and the security deposit was $3,895. On September 15, 2018, the Company amended the lease agreement to extend it until September 14, 2020 and increase the monthly base rent and security deposit to $4,012. The Company’s rent expense for this space amounted to $11,747 and $11,685 for the three months ended September 30, 2018 and 2017, respectively, and $35,117 and 35,055 for the nine months ended September 30, 2018 and 2017, respectively.

Research and Development Activities

The VP of R&D is the sole owner and President of a company that performs contract engineering services for the Company. During the three and nine months ended September 30, 2018, the Company recognized research and development expense of $243,614 and $672,057, respectively, related to services provided by such vendor. During the three and nine months ended September 30, 2017, the Company recognized research and development expense of $100,721 and $660,846, respectively, related to services provided by such vendor. As of September 30, 2018 and December 31, 2017, the Company had a liability of $178,209 and $94,998, respectively, to the vendor and a liability of $0 and $9,906, respectively, related to expenses incurred by the VP of R&D.

The Company recognized $46,050 and $128,550, respectively, of compensation expense related to the VP of R&D’s salary during the three and nine months ended September 30, 2018. The Company recognized $0 of compensation expense during the three and nine months ended September 30, 2017.

During 2015, the Company entered into a license agreement with Senju Pharmaceutical Co., Lt. (“Senju”) whereby the Company agreed to grant to Senju an exclusive, royalty-bearing license for its micro-dose product candidates for Asia to sublicense, develop, make, have made, manufacture, use, import, market, sell, and otherwise distribute the micro-dose product candidates. In consideration for the license, Senju agreed to pay to Eyenovia five percent (5%) royalties for the term of the license agreement. The agreement shall continue in full force and effect, on a country-by-country basis, until the latest to occur of: (i) the tenth (10th) anniversary of the first commercial sale of a micro-dose product candidate in Asia; or (ii) the expiration of the licensed patents. As of the date of this filing, there had been no commercial sales of a micro-dose product candidate in Asia, such that no royalties had been earned. Senju is owned by the family of a member of the Company’s Board of Directors and both beneficially own greater than 5% of the Company’s common stock.

Stockholders' Equity

9 Months Ended

Sep. 30, 2018

Equity [Abstract]

Stockholders' Equity Note Disclosure [Text Block]

Note 7 – Stockholders’ Equity

Authorized Capital

On January 29, 2018, in connection with its IPO and the conversion of all then existing preferred stock into common stock, the Company filed its Third Amended and Restated Certificate of Incorporation (the “Third Amendment”) with the Secretary of State of the State of Delaware, effective the same day. Pursuant to the Third Amendment, the Company is authorized to issue 90,000,000 shares of common stock and 6,000,000 shares of preferred stock. The holders of the Company’s common stock are entitled to one vote per share. No shares of preferred stock were designated. Pursuant to the Third Amendment, the Board of Directors is empowered, without stockholder approval, to issue preferred stock with dividend, liquidation, redemption, voting or other rights.

Equity Incentive Plans

On January 5, 2018, the Company’s Board of Directors and stockholders approved an amendment to the Company’s 2014 Equity Incentive Plan (“2014 Plan”) to increase the number of shares of common stock authorized under the 2014 Plan from 1,733,333 shares to 1,866,667 shares.

On March 6, 2018, the Company’s Board of Directors adopted the 2018 Omnibus Stock Incentive Plan (“2018 Plan”), subject to stockholder approval. The 2018 Plan provides for the issuance of incentive stock options, nonstatutory stock options, rights to purchase common stock, stock appreciation rights, restricted stock and restricted stock units (“RSUs”) to employees, directors and consultants of the Company and its affiliates. The 2018 Plan was approved by Company stockholders at its annual meeting of stockholders on June 11, 2018. The 2018 Plan terminates on June 11, 2028. The 2018 Plan requires the exercise price of stock options to be greater than or equal to the fair value of the Company’s common stock on the date of grant. There are 750,000 shares of common stock authorized under the 2018 Plan.

Conversion of Preferred Stock

Immediately prior to the closing of the IPO on January 29, 2018, all outstanding shares of preferred stock were automatically converted into an aggregate of 4,702,116 shares of the Company’s common stock.

Initial Public Offering

On January 29, 2018, the Company consummated its IPO of 2,730,000 shares of its common stock at an offering price of $10.00 per share, generating $27.3 million and $24.5 million in gross and net proceeds, respectively. Underwriting discounts, commissions and other offering expenses were approximately $2.8 million, which were recorded as a reduction of additional paid-in capital.

Stock Warrants

During the three months ended September 30, 2018, warrants to purchase an aggregate of 61,875 shares of common stock with an exercise price of $0.04 per share were exercised on a cashless basis, which resulted in the issued of an aggregate of 61,385 shares of common stock.

Stock-Based Compensation

The Company records stock-based compensation expense related to stock options and RSUs. For the three months ended September 30, 2018 and 2017, the Company recorded such expense of $462,945 and $206,021, respectively, and for the nine months ended September 30, 2018 and 2017, the Company recorded such expense of $1,115,034 and $212,411, respectively. As of September 30, 2018, there was $4,451,796 of unrecognized stock-based compensation expense (of which, $644,631

related to non-employee grants, which are subject to fair value adjustments

), which the Company expects to recognize over a weighted average period of 2.4 years.

Restricted Stock Units

On July 24, 2018, the Company granted an aggregate of 20,165 RSUs to its directors under the 2018 Plan. The grants vest on the earlier of (i) the one-year anniversary of the date of grant and (ii) the date of the 2019 annual stockholders meeting, subject to the grantee remaining on the Board until then. The RSUs had a grant date fair value of $125,000, which will be recognized over the vesting period.

Stock Options

On April 16, 2018, the Compensation Committee of the Board of Directors approved the grant of ten-year stock options to purchase 175,668 shares of common stock to Company employees and consultants under the 2014 Plan. The stock options will vest in equal monthly increments over 36 months beginning on the one-month anniversary of the date of grant, subject to continued service to the Company, and have an exercise price of $8.72 per share, which represents the closing stock price on the date of grant. The stock options had a grant date fair value of $1,412,700, which the Company expects to recognize over the vesting period.

During the three months ended September 30, 2018, the Company granted ten-year stock options to purchase an aggregate of 393,999 shares of common stock to its employees, consultants and directors under the 2018 Plan. Of the 393,999 shares, (i) 311,674 vest over three years from the date of grant with one-third vesting on the one-year anniversary of the date of grant and the balance vesting monthly over the remaining 24 months, subject to continued service to the Company, (ii) 60,000 vest monthly over 36 months beginning on the one-month anniversary of the date of grant, subject to continued service to the Company, and (iii) 22,325 vest on the earlier of the one-year anniversary of the date of grant and the date of the 2019 annual stockholders meeting, subject to continued service to the Company. The stock options have exercise prices ranging from $5.10 per share to $6.30 per share, which represents the Company’s closing stock price on the date of grant. The stock options had a grant date value of $2,230,000, which the Company expects to recognize over the vesting period.

In applying the Black-Scholes option pricing model to stock options granted, the Company used the following approximate assumptions:

	For the Three Months Ended						For the Nine Months Ended
	September 30,						September 30,
	2018			2017			2018			2017
Expected term (years)		5.50 - 10.00			5.32 - 10.00			5.50 - 10.00			5.32 - 10.00
Risk free interest rate		2.74 - 2.95	%		1.89 - 2.39	%		2.69 - 2.95	%		1.89 - 2.39	%
Expected volatility		141	%		130	%		140 - 141	%		130	%
Expected dividends		0.00	%		0.00	%		0.00	%		0.00	%

The Company has computed the fair value of stock options granted using the Black-Scholes option pricing model. Option forfeitures are accounted for at the time of occurrence. The expected term used for options issued to non-employees is usually the contractual life and the expected term used for options issued to employees and directors is the estimated period of time that options granted are expected to be outstanding. The Company utilizes the “simplified” method to develop an estimate of the expected term of “plain vanilla” employee option grants. The Company does not yet have a trading history to support its historical volatility calculations. Accordingly, the Company is utilizing an expected volatility figure based on a review of the historical volatility of comparable entities over a period of time equivalent to the expected life of the instrument being valued. The risk-free interest rate was determined from the implied yields from U.S. Treasury zero-coupon bonds with a remaining term consistent with the expected term of the instrument being valued.

The weighted average estimated grant date fair value of the stock options granted for the three and nine months ended September 30, 2018 was approximately $5.66 and $6.39 per share, respectively. The weighted average estimated grant date fair value of the stock options granted for the three and nine months ended September 30, 2017 was approximately $1.84 per share.

A summary of the option activity during the nine months ended September 30, 2018 is presented below:

						Weighted
				Weighted		Average
				Average		Remaining		Aggregate
	Number of			Exercise		Life		Intrinsic
	Options			Price		In Years		Value
Outstanding January 1, 2018		1,684,416		$	1.68
Granted		569,667			6.95
Exercised		(28,965	)		1.95
Forfeited		-			-
Outstanding September 30, 2018		2,225,118		$	3.03		8.2	$	3,913,082

Exercisable September 30, 2018		1,181,926		$	1.68		7.3	$	2,903,941

The following table presents information related to stock options as of September 30, 2018:

Options Outstanding				Options Exercisable
				Weighted
		Outstanding		Average		Exercisable
Exercise		Number of		Remaining Life		Number of
Price		Options		In Years		Options
$	1.24		760,001		6.5		760,001
$	1.95		868,782		8.8		381,275
$	5.10		6,000		-		-
$	5.19		16,500		-		-
$	5.25		26,668		8.0		12,917
$	6.20		311,499		-		-
$	6.30		60,000		9.8		3,333
$	8.72		175,668		9.5		24,400
			2,225,118		7.3		1,181,926

Summary of Significant Accounting Policies (Policies)

9 Months Ended

Sep. 30, 2018

Accounting Policies [Abstract]

Liquidity and Financial Condition [Policy Text Block]

Liquidity and Financial Condition

Cash and Cash Equivalents, Policy [Policy Text Block]

Cash

Reclassification, Policy [Policy Text Block]

Reclassifications

Earnings Per Share, Policy [Policy Text Block]

Net Loss Per Common Share

The following securities are excluded from the calculation of weighted average diluted common shares because their inclusion would have been anti-dilutive:

	September 30,
	2018		2017
Options		2,225,118		1,684,409
Series A Convertible Preferred Stock		-		2,932,431
Series A-2 Convertible Preferred Stock		-		788,827
Series B Convertible Preferred Stock		-		918,949
Total potentially dilutive shares		2,225,118		6,324,616

New Accounting Pronouncements, Policy [Policy Text Block]

Recent Accounting Pronouncements

are effective for emerging growth companies for fiscal years beginning

after December 15, 2019. The Company is currently evaluating ASU 2018-10 and its impact on its financial position, results of operations and cash flows.

are effective for emerging growth companies for fiscal years beginning

after December 15, 2019. The Company is currently evaluating ASU 2018-11 and its impact on its financial position, results of operations and cash flows.

Stockholders' Equity (Tables)

9 Months Ended

Sep. 30, 2018

Equity [Abstract]

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]

In applying the Black-Scholes option pricing model to stock options granted, the Company used the following approximate assumptions:

	For the Three Months Ended						For the Nine Months Ended
	September 30,						September 30,
	2018			2017			2018			2017
Expected term (years)		5.50 - 10.00			5.32 - 10.00			5.50 - 10.00			5.32 - 10.00
Risk free interest rate		2.74 - 2.95	%		1.89 - 2.39	%		2.69 - 2.95	%		1.89 - 2.39	%
Expected volatility		141	%		130	%		140 - 141	%		130	%
Expected dividends		0.00	%		0.00	%		0.00	%		0.00	%

Share-based Compensation, Stock Options, Activity [Table Text Block]

A summary of the option activity during the nine months ended September 30, 2018 is presented below:

						Weighted
				Weighted		Average
				Average		Remaining		Aggregate
	Number of			Exercise		Life		Intrinsic
	Options			Price		In Years		Value
Outstanding January 1, 2018		1,684,416		$	1.68
Granted		569,667			6.95
Exercised		(28,965	)		1.95
Forfeited		-			-
Outstanding September 30, 2018		2,225,118		$	3.03		8.2	$	3,913,082

Exercisable September 30, 2018		1,181,926		$	1.68		7.3	$	2,903,941

Schedule Of Share Based Compensation Shares Outstanding UnderStock Option Plans By Exercise Price Range [Table Text Block]

The following table presents information related to stock options as of September 30, 2018:

Options Outstanding				Options Exercisable
				Weighted
		Outstanding		Average		Exercisable
Exercise		Number of		Remaining Life		Number of
Price		Options		In Years		Options
$	1.24		760,001		6.5		760,001
$	1.95		868,782		8.8		381,275
$	5.10		6,000		-		-
$	5.19		16,500		-		-
$	5.25		26,668		8.0		12,917
$	6.20		311,499		-		-
$	6.30		60,000		9.8		3,333
$	8.72		175,668		9.5		24,400
			2,225,118		7.3		1,181,926

Prepaid Expenses and Other Current Assets (Details) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Prepaid Expense and Other Assets [Abstract]
Prepaid research and development expenses	$ 103,502	$ 28,932
Prepaid patent expenses	16,489	7,833
Prepaid insurance expenses	132,563	384
Prepaid marketing expenses	24,000	0
Prepaid rent and security deposit	21,896	0
Total prepaid expenses and other current assets	$ 298,450	$ 37,149

Accrued Expenses and Other Current Liabilities (Details) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Accrued bonus expenses	$ 350,000	$ 0
Accrued payroll expenses	132,306	0
Accrued research and development expenses	148,020	120,455
Accrued legal settlement	150,000	0
Accrued legal expenses	40,411	0
Credit card payable	40,156	9,843
Accrued rent expenses	12,469	0
Accrued professional services	6,400	41,831
Accrued offering costs	0	133,000
Other	9,222	1,134
Total accrued expenses and other current liabilities	$ 888,984	$ 306,263

Commitments and Contingencies (Details)	Sep. 30, 2018 USD ($)
2018	$ 98,167
2019	238,300
2020	244,853
2021	251,586
2022	258,505
2023	198,156
Minimum Lease Payments	$ 1,289,567

Commitments and Contingencies (Details Textual)		1 Months Ended	3 Months Ended		9 Months Ended
Commitments and Contingencies (Details Textual)	Aug. 08, 2018 USD ($) ft²	Oct. 29, 2018 USD ($)	Sep. 30, 2018 USD ($)	Sep. 30, 2017 USD ($)	Sep. 30, 2018 USD ($)	Sep. 30, 2017 USD ($)	Dec. 31, 2017 USD ($)
Loss Contingency, Damages Sought, Value					$ 1,100,000
Malpractice Loss Contingency, Insurance Recoveries					10,000,000
Net Rentable Area \| ft²	3,800
Operating Leases, Rent Expense	$ 1,290,000		$ 8,000	$ 9,000	32,000	$ 27,000
Security Deposit	$ 118,000		$ 117,800		117,800		$ 0
Lease Expiration Date	Sep. 30, 2023
Loss Contingency Accrual, Payments					150,000
Malpractice Loss Contingency, Claims Incurred in Period					$ 450,000
Subsequent Event [Member]
Loss Contingency, Damages Sought, Value		$ 600,000
Minimum [Member]
Operating Leases, Rent Expense, Minimum Rentals	$ 19,633
Maximum [Member]
Operating Leases, Rent Expense, Minimum Rentals	$ 22,486

Related Party Transactions (Details Textual)			1 Months Ended				3 Months Ended		9 Months Ended		12 Months Ended
Related Party Transactions (Details Textual)	Aug. 08, 2018 USD ($) ft²	Jul. 06, 2017 USD ($)	Sep. 15, 2018 USD ($)	Jan. 31, 2018 USD ($)	Sep. 15, 2016 USD ($) ft²	Jul. 31, 2016 USD ($)	Sep. 30, 2018 USD ($)	Sep. 30, 2017 USD ($)	Sep. 30, 2018 USD ($)	Sep. 30, 2017 USD ($)	Dec. 31, 2017 USD ($)	Dec. 31, 2015
Operating Leases, Rent Expense	$ 1,290,000						$ 8,000	$ 9,000	$ 32,000	$ 27,000
Net Rentable Area \| ft²	3,800
Security Deposit	$ 118,000						117,800		117,800		$ 0
Share-based Compensation							$ 462,945	206,021	$ 1,115,034	212,411
Minority Interest Ownership Percentage In Company							5.00%		5.00%
Payments for Rent				$ 4,000		$ 3,000
Vice President of Research and Development [Member]
Cost Of Services Engineering Services							$ 243,614	100,721	$ 672,057	660,846
Net Rentable Area \| ft²					953
Lease, Monthly Base Rent			$ 4,012		$ 3,895
Operating Lease, Expense							11,747	11,685	35,117	35,055
Security Deposit			$ 4,012		$ 3,895
Share-based Compensation							46,050	0	$ 128,550	0
Senju Pharmaceutical Co [Member]
Royalty Percentage												5.00%
License Agreement Expiry Period Description									The agreement shall continue in full force and effect, on a country-by-country basis, until the latest to occur of: (i) the tenth (10th) anniversary of the first commercial sale of a micro-dose product candidate in Asia; or (ii) the expiration of the licensed patents.
Research and Development Expense [Member] \| Vice President of Research and Development [Member]
Due to Related Parties							178,209		$ 178,209		94,998
Related to expenses incurred									0		$ 9,906
Cura Partners [Member] \| Consulting Agreement [Member]
Consulting agreement payment, Per month		$ 9,567
Consulting agreement payment, Per hour		$ 250
Cura Partners [Member] \| General and Administrative Expense [Member] \| Consulting Agreement [Member]
Related Party Transaction, Expenses from Transactions with Related Party							$ 35,018	25,509	127,478	25,509
Private Medical Equity, Inc. [Member]
Consulting Fee									$ 33,200
Private Medical Equity, Inc. [Member] \| Consulting Agreement [Member]
Related Party Transaction, Expenses from Transactions with Related Party								47,000		329,000
Private Medical Equity, Inc. [Member] \| Research and Development Expense [Member] \| Consulting Agreement [Member]
Related Party Transaction, Expenses from Transactions with Related Party								25,192		176,344
Private Medical Equity, Inc. [Member] \| General and Administrative Expense [Member] \| Consulting Agreement [Member]
Related Party Transaction, Expenses from Transactions with Related Party								$ 21,808		$ 152,656

Stockholders' Equity (Details 1) - USD ($)	1 Months Ended	3 Months Ended		9 Months Ended
Stockholders' Equity (Details 1) - USD ($)	Apr. 16, 2018	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Number of Options Outstanding \| Shares				1,684,416
Number of Options Granted \| Shares	175,668	393,999		569,667
Number of Options Exercised \| Shares				(28,965)
Number of Options Forfeited \| Shares				0
Number of Options Outstanding \| Shares		2,225,118		2,225,118
Number of Options Exercisable \| Shares		1,181,926		1,181,926
Weighted Average Exercise Price, Outstanding \| $ / Shares				$ 1.68
Weighted Average Exercise Price, Granted \| $ / Shares	$ 8.72	$ 5.66	$ 1.84	6.95	$ 1.84
Weighted Average Exercise Price, Exercised \| $ / Shares				1.95
Weighted Average Exercise Price, Forfeited \| $ / Shares				0
Weighted Average Exercise Price, Outstanding \| $ / Shares		3.03		3.03
Weighted Average Exercise Price, Exercisable \| $ / Shares		$ 1.68		$ 1.68
Weighted Average Remaining Life In Years, Outstanding				8 years 2 months 12 days
Weighted Average Remaining Life In Years, Exercisable				7 years 3 months 18 days
Aggregate Intrinsic Value, Outstanding \| $		$ 3,913,082		$ 3,913,082
Aggregate Intrinsic Value, Exercisable \| $		$ 2,903,941		$ 2,903,941

Stockholders' Equity (Details 2)	9 Months Ended
Stockholders' Equity (Details 2)	Sep. 30, 2018 $ / shares shares
Options Outstanding, Outstanding Number of Options	2,225,118
Options Exercisable, Weighted Average Remaining Life In Years	7 years 3 months 18 days
Options Exercisable, Exercisable Number of Options	1,181,926
Exercise Price 1.24 [Member]
Options Outstanding, Outstanding Exercise Price \| $ / shares	$ 1.24
Options Outstanding, Outstanding Number of Options	760,001
Options Exercisable, Weighted Average Remaining Life In Years	6 years 6 months
Options Exercisable, Exercisable Number of Options	760,001
Exercise Price 1.95 [Member]
Options Outstanding, Outstanding Exercise Price \| $ / shares	$ 1.95
Options Outstanding, Outstanding Number of Options	868,782
Options Exercisable, Weighted Average Remaining Life In Years	8 years 9 months 18 days
Options Exercisable, Exercisable Number of Options	381,275
Exercise Price 5.10 [Member]
Options Outstanding, Outstanding Exercise Price \| $ / shares	$ 5.10
Options Outstanding, Outstanding Number of Options	6,000
Options Exercisable, Exercisable Number of Options	0
Exercise Price 5.19 [Member]
Options Outstanding, Outstanding Exercise Price \| $ / shares	$ 5.19
Options Outstanding, Outstanding Number of Options	16,500
Options Exercisable, Exercisable Number of Options	0
Exercise Price 5.25 [Member]
Options Outstanding, Outstanding Exercise Price \| $ / shares	$ 5.25
Options Outstanding, Outstanding Number of Options	26,668
Options Exercisable, Weighted Average Remaining Life In Years	8 years
Options Exercisable, Exercisable Number of Options	12,917
Exercise Price 6.20 [Member]
Options Outstanding, Outstanding Exercise Price \| $ / shares	$ 6.20
Options Outstanding, Outstanding Number of Options	311,499
Options Exercisable, Exercisable Number of Options	0
Exercise Price 6.30 [Member]
Options Outstanding, Outstanding Exercise Price \| $ / shares	$ 6.30
Options Outstanding, Outstanding Number of Options	60,000
Options Exercisable, Weighted Average Remaining Life In Years	9 years 9 months 18 days
Options Exercisable, Exercisable Number of Options	3,333
Exercise Price 8.72 [Member]
Options Outstanding, Outstanding Exercise Price \| $ / shares	$ 8.72
Options Outstanding, Outstanding Number of Options	175,668
Options Exercisable, Weighted Average Remaining Life In Years	9 years 6 months
Options Exercisable, Exercisable Number of Options	24,400

Stockholders' Equity (Details Textual) - USD ($)	1 Months Ended				3 Months Ended		9 Months Ended
Stockholders' Equity (Details Textual) - USD ($)	Jul. 24, 2018	Apr. 16, 2018	Jan. 29, 2018	Jan. 08, 2018	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Mar. 06, 2018	Jan. 05, 2018	Dec. 31, 2017
Common Stock, Shares Authorized			90,000,000		90,000,000		90,000,000				90,000,000
Preferred Stock, Shares Authorized			6,000,000		6,000,000		6,000,000				6,000,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options					$ 4,451,796		$ 4,451,796
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition							2 years 4 months 24 days
Convertible Preferred Stock, Shares Issued upon Conversion			4,702,116
Share-based Compensation Arrangement by Share-based Payment Award, Description					vest over three years from the date of grant with one-third vesting on the one-year anniversary of the date of grant and the balance vesting monthly over the remaining 24 months
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Grant Date Intrinsic Value		$ 1,412,700
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period		36 months
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross		175,668			393,999		569,667
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price		$ 8.72			$ 5.66	$ 1.84	$ 6.95	$ 1.84
Share-based Compensation					$ 462,945	$ 206,021	$ 1,115,034	$ 212,411
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period	20,165
Sharebased Compensation Arrangement by Sharebased Payment Award Options Grants in Period Grant Date Fair Value					$ 2,230,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value	$ 125,000
Stockholders' Equity, Reverse Stock Split				1-for-3.75
Class of Warrant or Right, Exercise Price of Warrants or Rights					$ 0.04		$ 0.04
Class of Warrant or Right, Number of Securities Called by Warrants or Rights					61,875		61,875
Warrant [Member]
Stock Issued During Period, Shares, New Issues					61,385
Share-based Compensation Award, Tranche One [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross					311,674
Share-based Compensation Award, Tranche Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period					36 months
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross					60,000
Share-based Compensation Award, Tranche Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross					22,325
Non-Employee Grants [Member]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options					$ 644,631		$ 644,631
Maximum [Member]
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price					$ 6.30
Minimum [Member]
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price					$ 5.10
2014 Equity Incentive Plan [Member] \| Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized										1,866,667
2014 Equity Incentive Plan [Member] \| Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized										1,733,333
Omnibus Stock Incentive Plan 2018 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized									750,000
IPO [Member]
Stock Issued During Period, Shares, New Issues			2,730,000
Shares Issued, Price Per Share			$ 10.00
Net Proceeds from Issuance of Common Stock			$ 24,500,000
Payment of Financing and Stock Issuance Costs			2,800,000
Gross Proceeds Of Stock Value Issued During Period			$ 27,300,000

Condensed Statements of Cash Flows (Parenthetical)	9 Months Ended
Condensed Statements of Cash Flows (Parenthetical)	Sep. 30, 2018 USD ($)
Stock Issued During Period, Value, New Issues	$ 27,300,000
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs	$ 2,211,000

Stockholders' Equity (Details)	3 Months Ended		9 Months Ended
Stockholders' Equity (Details)	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Risk free interest rate, Minimum	2.74%	1.89%	2.69%	1.89%
Risk free interest rate, Maximum	2.95%	2.39%	2.95%	2.39%
Expected volatility	141.00%	130.00%		130.00%
Expected dividends	0.00%	0.00%	0.00%	0.00%
Maximum [Member]
Expected term (years)	10 years	10 years	10 years	10 years
Expected volatility			141.00%
Minimum [Member]
Expected term (years)	5 years 6 months	5 years 3 months 25 days	5 years 6 months	5 years 3 months 25 days
Expected volatility			140.00%

Summary of Significant Accounting Policies (Details) - shares	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	2,225,118	6,324,616
Options
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	2,225,118	1,684,409
Series A Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	0	2,932,431
Series A-2 Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	0	788,827
Series B Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	0	918,949